Fluorouracil in colorectal cancer — A tale of two drugs: Implications for biochemical modulation Journal Article


Authors: Sobrero, A. F.; Aschele, C.; Bertino, J. R.
Article Title: Fluorouracil in colorectal cancer — A tale of two drugs: Implications for biochemical modulation
Abstract: Purpose: To determine if fluorouracil (FUra) has different mechanisms of action as a function of the dose schedule used, Design: The preclinical and clinical literature relating toxicity and antitumor effects of FUra as a function of its dose schedule, with and without modulating agents, was reviewed, Results: The data support the hypothesis that FUra may be considered to be two different drugs, depending on its dose schedule (bolus v continuous infusion [CI]). Conclusion: These results suggest that additional therapeutic benefit may be obtained from FUra regimens by (1) appropriate schedule-dependent modulation, (2) the sequential or alternating use of cycles of bolus followed by cycles of CI FUra appropriately modulated, or (3) hybrid regimens, ie, those that contain both pulse and CI schedules. (C) 1997 by American Society of Clinical Oncology.
Keywords: spectroscopy; quality-of-life; phase-iii trial; magnetic-resonance; prospective randomized trial; continuous-infusion fluorouracil; tumor-cell-lines; dose folinic acid; atlantic oncology program; dependent cyto-toxicity; human-colon
Journal Title: Journal of Clinical Oncology
Volume: 15
Issue: 1
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1997-01-01
Start Page: 368
End Page: 381
Language: English
ACCESSION: WOS:A1997WB90700049
PROVIDER: wos
PUBMED: 8996164
DOI: 10.1200/JCO.1997.15.1.368
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph Bertino
    363 Bertino